Latest Annual Report
Filed: 2026-02-26
Key Insights
- C4 Therapeutics, Inc. (CCCC) reported financial results for the full year 2025, with a focus on the company's collaborative agreements, development pipeline, and capital raising activities.
- The company's revenue was primarily driven by milestone payments from its collaborations, including the Betta Pharma stock purchase agreement and its at-the-market equity program.
- C4 Therapeutics continued to invest in its research and development efforts, expanding its laboratory equipment and adding new employee headcount to support its pipeline of protein degradation development candidates.